St Vincent’s Institute of Medical Research (SVI) in Melbourne, Australia, today announced the extension of the research and licensing collaboration agreement with Janssen Pharmaceuticals, part of US healthcare giant Johnson & Johnson (NYSE: JNJ), with focus on Alzheimer’s disease treatment.
The objective of the initiative is to develop and potentially commercialize small molecule modulators of microglial function and inflammation. The collaboration was facilitated by Johnson & Johnson Innovation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze